StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Warrants

<< Previous

Bullboard Posts

Next >>

Comment by HollywoodHusson Mar 31, 2021 4:28pm

187 Views

Post# 32916541

RE:RE:RE:RE:RE:Warrants

My question for warrants was will price go up in relation to potential buy out price. Say it's the 2B buyout at $44 a share. With the calculation of that if the stock went to $44. The warrants would then be priced at $5.41 CAD? Would these prices be reflective in the market on the exchange?

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale